458 related articles for article (PubMed ID: 29197738)
21. Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary.
Roman MW; Wilkinson SM
Issues Ment Health Nurs; 2014 Dec; 35(12):972-4. PubMed ID: 25426751
[TBL] [Abstract][Full Text] [Related]
22. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo.
Bundgaard C; Eneberg E; Sánchez C
Neuropharmacology; 2016 Apr; 103():104-11. PubMed ID: 26700248
[TBL] [Abstract][Full Text] [Related]
23. Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis.
Tomlinson A; Efthimiou O; Boaden K; New E; Mather S; Salanti G; Imai H; Ogawa Y; Tajika A; Kishimoto S; Kikuchi S; Chevance A; Furukawa TA; Cipriani A
Evid Based Ment Health; 2019 May; 22(2):61-66. PubMed ID: 30996028
[TBL] [Abstract][Full Text] [Related]
24. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320
[TBL] [Abstract][Full Text] [Related]
25. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis.
Reichenpfader U; Gartlehner G; Morgan LC; Greenblatt A; Nussbaumer B; Hansen RA; Van Noord M; Lux L; Gaynes BN
Drug Saf; 2014 Jan; 37(1):19-31. PubMed ID: 24338044
[TBL] [Abstract][Full Text] [Related]
26. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone.
McIntyre RS
Neuropsychiatr Dis Treat; 2017; 13():2913-2919. PubMed ID: 29238196
[TBL] [Abstract][Full Text] [Related]
27. Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.
Gartlehner G; Thieda P; Hansen RA; Gaynes BN; Deveaugh-Geiss A; Krebs EE; Lohr KN
Drug Saf; 2008; 31(10):851-65. PubMed ID: 18759509
[TBL] [Abstract][Full Text] [Related]
28. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
29. The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis.
Gartlehner G; Thaler K; Hansen RA; Gaynes BN
Drug Saf; 2009; 32(12):1159-73. PubMed ID: 19916583
[TBL] [Abstract][Full Text] [Related]
30. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
Berhan A; Barker A
BMC Psychiatry; 2014 Sep; 14():276. PubMed ID: 25260373
[TBL] [Abstract][Full Text] [Related]
31. Levomilnacipran and Vortioxetine for Adults with Major Depressive Disorder.
Scarff JR
J S C Med Assoc; 2015 Dec-2016 Jan; 111(4):131-3. PubMed ID: 27141705
[No Abstract] [Full Text] [Related]
32. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Alam MY; Jacobsen PL; Chen Y; Serenko M; Mahableshwarkar AR
Int Clin Psychopharmacol; 2014 Jan; 29(1):36-44. PubMed ID: 24169027
[TBL] [Abstract][Full Text] [Related]
33. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis.
Gartlehner G; Hansen RA; Morgan LC; Thaler K; Lux L; Van Noord M; Mager U; Thieda P; Gaynes BN; Wilkins T; Strobelberger M; Lloyd S; Reichenpfader U; Lohr KN
Ann Intern Med; 2011 Dec; 155(11):772-85. PubMed ID: 22147715
[TBL] [Abstract][Full Text] [Related]
34. Evidence synthesis, practice guidelines and real-world prescriptions of new generation antidepressants in the treatment of depression: a protocol for cumulative network meta-analyses and meta-epidemiological study.
Luo Y; Chaimani A; Kataoka Y; Ostinelli EG; Ogawa Y; Cipriani A; Salanti G; Furukawa TA
BMJ Open; 2018 Dec; 8(12):e023222. PubMed ID: 30530583
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder.
Brignone M; Diamand F; Painchault C; Takyar S
Curr Med Res Opin; 2016; 32(2):351-66. PubMed ID: 26637048
[TBL] [Abstract][Full Text] [Related]
36. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
Baldwin DS; Chrones L; Florea I; Nielsen R; Nomikos GG; Palo W; Reines E
J Psychopharmacol; 2016 Mar; 30(3):242-52. PubMed ID: 26864543
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological and non-pharmacological treatments for major depressive disorder in adults: A systematic review and network meta-analysis.
Chen C; Shan W
Psychiatry Res; 2019 Nov; 281():112595. PubMed ID: 31627074
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.
Fu J; Chen Y
Psychopharmacology (Berl); 2015 Jan; 232(1):7-16. PubMed ID: 24871704
[TBL] [Abstract][Full Text] [Related]
39. Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial.
Clayton AH; Gommoll C; Chen D; Nunez R; Mathews M
Int Clin Psychopharmacol; 2015 Jul; 30(4):216-23. PubMed ID: 26039688
[TBL] [Abstract][Full Text] [Related]
40. Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians.
Gartlehner G; Dobrescu A; Chapman A; Toromanova A; Emprechtinger R; Persad E; Affengruber L; Pieh C; Klerings I; Wagner G
Ann Intern Med; 2023 Feb; 176(2):196-211. PubMed ID: 36689750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
